SKYX Registers 25.25M Deako Merger Shares for Resale; Nasdaq Governance Deficiency Disclosed

summarizeSummary

SKYX registered 25.25 million Deako merger shares for resale by MassMutual entities and Needham, with staggered lock-ups through 2028. The filing also discloses Nasdaq non-compliance on board independence and audit committee composition after a director's death, with a cure period through 2027.

check_boxKey Events · Financing and Capital Events · SKYX

• 25.25M Merger Shares Registered for Resale

  S-3 registers 25,250,000 shares issued in the Deako acquisition for resale by Massachusetts Mutual Life Insurance Company (12.5M), MassMutual Ascend Life Insurance Company (12.5M), and Needham & Company (250,000). Company receives no proceeds.

• Staggered Lock-Up Through 2028

  Shares release in four equal 25% tranches at 12, 15, 18, and 21 months after the October 13, 2026 closing — first tranche unlocks October 2027, final tranche July 2028.

• Nasdaq Governance Non-Compliance

  Company is not in compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A) after independent director Efrat L. Greenstein Brayer passed away on September 26, 2026. Cure period expires at the earlier of the next annual meeting or September 26, 2027 (or March 25, 2027 if the annual meeting is before that date).

• Resale Overhang Risk

  The 25.25 million registered shares represent approximately 18.28% of the 138.1 million shares outstanding as of October 12, 2026, prior to the merger issuance — a substantial potential supply overhang once lock-ups expire.

auto_awesomeAnalysis · SKYX · Manufacturing

SKYX filed an S-3 to register 25,250,000 shares issued in the Deako acquisition for resale by the selling securityholders — Massachusetts Mutual Life Insurance Company, MassMutual Ascend Life Insurance Company, and Needham & Company. The company receives no proceeds; the registration fulfills a contractual obligation under the merger agreement. The shares are subject to a staggered lock-up releasing in four equal 25% tranches at 12, 15, 18, and 21 months after the October 13, 2026 closing. Critically, the prospectus also discloses that SKYX is not in compliance with Nasdaq's board independence and audit committee composition requirements following the death of independent director Efrat L. Greenstein Brayer on September 26, 2026. The company has a cure period expiring at the earlier of its next annual meeting or September 26, 2027 (or March 25, 2027 if the annual meeting is before that date). Failure to regain compliance could lead to delisting. The resale overhang of 25.25 million shares — roughly 18% of the pre-merger outstanding count — combined with the governance deficiency creates meaningful downside risk for existing shareholders.